Prokidney (PROK) Income towards Parent Company (2021 - 2026)
Prokidney's (PROK) quarterly Income towards Parent Company came in at -$46.4 million in Q2 2026, down 25.62% year-over-year from -$62.4 million in Q2 2025, and down 8.95% quarter-over-quarter from -$42.6 million in Q1 2026.
Analysis
Prokidney (PROK) Income towards Parent Company (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported Income towards Parent Company for 6 consecutive years, with -$46.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Income towards Parent Company fell 25.62% year-over-year to -$46.4 million in Q2 2026; TTM through Jun 2026 was -$133.6 million, a 18.77% increase from a year earlier, with the FY2025 full-year figure at -$119.4 million, up 26.87% from the prior year.
- Income towards Parent Company was -$46.4 million for Q2 2026 at Prokidney, down from -$42.6 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$8.7 million in Q4 2025 and troughed at -$67.5 million in Q1 2022.
- A 5-year average of -$36.4 million and a median of -$36.9 million in 2023 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company plunged 15476123.78% in 2022 and jumped 82.08% in 2025, its largest moves.
- Over 5 years, Income towards Parent Company stood at -$24.6 million in 2022, then rose by 11.59% to -$21.7 million in 2023, then slumped by 123.18% to -$48.5 million in 2024, then jumped by 82.08% to -$8.7 million in 2025, then tumbled by 434.61% to -$46.4 million in 2026.
- The last three Income towards Parent Company figures came in at -$46.4 million (Q2 2026), -$42.6 million (Q1 2026), and -$8.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -46.44 Mn |
| Mar 31, 2026 | -42.62 Mn |
| Dec 31, 2025 | -8.69 Mn |
| Sep 30, 2025 | -35.84 Mn |
| Jun 30, 2025 | -36.97 Mn |
| Mar 31, 2025 | -37.95 Mn |
| Dec 31, 2024 | -48.48 Mn |
| Sep 30, 2024 | -41.05 Mn |
| Jun 30, 2024 | -38.47 Mn |
| Mar 31, 2024 | -35.33 Mn |
| Dec 31, 2023 | -21.72 Mn |
| Sep 30, 2023 | -41.99 Mn |
| Jun 30, 2023 | -34.82 Mn |
| Mar 31, 2023 | -36.91 Mn |
| Dec 31, 2022 | -24.57 Mn |
| Sep 30, 2022 | -33.95 Mn |
| Jun 30, 2022 | -22.13 Mn |
| Mar 31, 2022 | -67.49 Mn |
| Dec 31, 2021 | -13.82 Mn |
| Sep 30, 2021 | -17.02 Mn |